Study Comparing Pharmacogenetics-Guided Medication to Standard Dosing in Adults with Mood, Anxiety, or Psychotic Disorders

What this Trial Is About

Researchers are evaluating the benefits of pharmacogenetics-informed pharmacotherapy compared to usual dosing in psychiatric patients with mood, anxiety, or psychotic disorders. This international clinical trial aims to determine if using genetic testing to guide medication choices and dosages can improve treatment outcomes and reduce side effects. The study includes a 24-week randomized, controlled design with patient and rater blinding to assess these effects in real-world medical settings. Participants are assigned to one of two groups the intervention group receives personalized medication recommendations based on pharmacogenetic testing results, while the control group receives standard dosing without genetic information. Prescribing physicians in the intervention group are unblinded to genetic profiles to guide treatment, whereas those in the control group remain blinded until study completion. All patients will receive one of several predefined medications suitable for their diagnosis. During the 24 weeks, participants will be regularly assessed for recovery using the Patient Recovery Assessment scale and other measures including symptom response, remission, side effect burden, general wellbeing, and psychosocial functioning. Data on patient recovery and side effects will be collected to evaluate the clinical benefits of pharmacogenetics-guided therapy. The study involves inpatient and outpatient psychiatric treatment settings and requires participants to use a mobile phone application for passive monitoring throughout the trial.

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders